[3] Herbst, R.S., P. Baas, D.W. Kim, et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2...
[3] Herbst, R.S., P. Baas, D.W. Kim, et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016, 387(10027): 1540-1550. [4] Paz-Ares, L., D. Vicente, A. Tafre...
J.L.; Han, J.-Y.; Molina, J.; Kim, J.-H.; Arvis, C.D.; Ahn, M.-J.; et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomi...
其中PD-L1阳性表达≥1%的患者占33.7%,PD-L1阳性表达≥50%的患者占10.8%。以前的研究还表明,PD-L1的表达与肿瘤样本的类型、切除与活检样本、原发性与转移性癌症的活检有关。临床试验表明,帕博利珠单抗(Pembrolizumab)或纳武利尤单抗(Nivolumab)联合治疗可以显著改善患者的预后。然而,抗PD-1/PD-L1免疫疗法对EGFR敏感...
CPS:联合阳性评分(Combined Positive Score) 定义:每100个肿瘤细胞中 PD-L1染色的肿瘤细胞和肿瘤相关的免疫细胞数之和,即CPS=(PD-L1膜染色阳性肿瘤细胞+PD-L1膜染色阳性肿瘤相关免疫细胞(淋巴细胞、巨噬细胞))/总肿瘤细胞数 x100。 IPS免疫细胞阳性比例分数(Immune cell Proportion Score)定义:任何强度PD-L1膜和...
免疫组织化学(immunohistochemistry,IHC,简称免疫组化)检测是评估肿瘤组织PD-L1表达状态的一种有效且最常用方法,广泛应用于包括非小细胞肺癌(non-small cell lung cancer, NSCLC)等在内的多种恶性肿瘤中,以识别或辅助预测可能从免疫治疗中获益的患者。 为更好地指导临床检测,中国抗癌协会肿瘤病理专业委员会肺癌学组...
[20]MURO K, CHUNG H C, SHANKARAN V, et al. Pembrolizumab for patients with PD-l1-positive advanced gastric cancer (keynote012): a multicentre, open-label, phase 1b trial[J]. The Lancet Oncology, 2016, 17(6): 717-726. DOI: 10.1016/s1470-2045(16)00175-3. ...
可手术且临床分期为I至III期的NSCLC患者均可纳入本研究,并在术前收集活检肿瘤样本,进行 AmoyDx Pan Lung Cancer PCR Panel(Multi-PCR 检测),检测基因包括EGFR、ALK、ROS1、KRAS、BRAF、HER2、RET、MET和NTRK基因在内的驱动基因。在手术后再次采集肿瘤样本,并使用新一代测序系统Oncomine Precision Assay (OPA)分析50...
There are examples of both positive and negative regulators of this process. While positive regulators boost anti-tumor activity, negative regulators impede the killing process and instead promote the growth of tumors. Therefore, an immunotherapy that targets the negative regulators to increase anti-...
2. Herbst, R.S., et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016. 387(10027): p. 1540-50. 3. Borghaei, H., et al., Nivolumab versus Docetaxel in Advanced ...